| Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection DS Khoury, D Cromer, A Reynaldi, TE Schlub, AK Wheatley, JA Juno, ... Nature medicine 27 (7), 1205-1211, 2021 | 3942 | 2021 |
| Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization S Cele, L Jackson, DS Khoury, K Khan, T Moyo-Gwete, H Tegally, JE San, ... Nature, 1-5, 2021 | 1447* | 2021 |
| Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis D Cromer, M Steain, A Reynaldi, TE Schlub, AK Wheatley, JA Juno, ... The Lancet Microbe 3 (1), e52-e61, 2022 | 589 | 2022 |
| Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 AK Wheatley, JA Juno, JJ Wang, KJ Selva, A Reynaldi, HX Tan, WS Lee, ... Nature communications 12 (1), 1-11, 2021 | 379 | 2021 |
| The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy D Cromer, AJ van Hoek, M Jit, WJ Edmunds, D Fleming, E Miller Journal of Infection 68 (4), 363-371, 2014 | 282 | 2014 |
| Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection D Cromer, JA Juno, D Khoury, A Reynaldi, AK Wheatley, SJ Kent, ... Nature Reviews Immunology 21 (6), 395-404, 2021 | 275 | 2021 |
| Functional cure of HIV: the scale of the challenge MP Davenport, DS Khoury, D Cromer, SR Lewin, AD Kelleher, SJ Kent Nature Reviews Immunology 19 (1), 45-54, 2019 | 139 | 2019 |
| Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice P Pymm, A Adair, LJ Chan, JP Cooney, FL Mordant, CC Allison, E Lopez, ... Proceedings of the National Academy of Sciences 118 (19), 2021 | 130 | 2021 |
| Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? SJ Kent, DS Khoury, A Reynaldi, JA Juno, AK Wheatley, E Stadler, ... Nature Reviews Immunology 22 (6), 387-397, 2022 | 128 | 2022 |
| Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models DS Khoury, AK Wheatley, MD Ramuta, A Reynaldi, D Cromer, ... Nature Reviews Immunology 20 (12), 727-738, 2020 | 125 | 2020 |
| Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection DS Khoury, TE Schlub, D Cromer, M Steain, Y Fong, PB Gilbert, ... Emerging Infectious Diseases 29 (2), 381, 2023 | 121 | 2023 |
| HIV reactivation from latency after treatment interruption occurs on average every 5-8 days—implications for HIV remission M Pinkevych, D Cromer, M Tolstrup, AJ Grimm, DA Cooper, SR Lewin, ... PLoS pathogens 11 (7), e1005000, 2015 | 120 | 2015 |
| Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England D Cromer, AJ van Hoek, AT Newall, AJ Pollard, M Jit The Lancet Public Health 2 (8), e367-e374, 2017 | 104 | 2017 |
| Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo AI Adekunle, M Pinkevych, R McGready, C Luxemburger, LJ White, ... PLoS neglected tropical diseases 9 (3), e0003595, 2015 | 101 | 2015 |
| Preferential invasion of reticulocytes during late-stage Plasmodium berghei infection accounts for reduced circulating reticulocyte levels D Cromer, KJ Evans, L Schofield, MP Davenport International journal for parasitology 36 (13), 1389-1397, 2006 | 100 | 2006 |
| Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis D Cromer, M Steain, A Reynaldi, TE Schlub, SR Khan, SC Sasson, ... Nature Communications 14 (1), 1633, 2023 | 97* | 2023 |
| Predicting the efficacy of variant-modified COVID-19 vaccine boosters DS Khoury, SS Docken, K Subbarao, SJ Kent, MP Davenport, D Cromer Nature Medicine 29 (3), 574-578, 2023 | 96 | 2023 |
| Early analysis of the Australian COVID-19 epidemic DJ Price, FM Shearer, MT Meehan, E McBryde, R Moss, N Golding, ... Elife 9, e58785, 2020 | 91 | 2020 |
| Clinical Assessment of Anti-Viral CD8+ T Cell Immune Monitoring Using QuantiFERON-CMV® Assay to Identify High Risk Allogeneic Hematopoietic Stem Cell Transplant Patients with … SK Tey, GA Kennedy, D Cromer, MP Davenport, S Walker, LI Jones, ... PLOS ONE 8 (10), e74744, 2013 | 91 | 2013 |
| Decay of Fc-dependent antibody functions after mild to moderate COVID-19 WS Lee, KJ Selva, SK Davis, BD Wines, A Reynaldi, R Esterbauer, ... Cell Reports Medicine 2 (6), 100296, 2021 | 83 | 2021 |
Timothy SchlubSydney School of Public Health, University of Sydneyبريد إلكتروني تم التحقق منه على sydney.edu.au